Left ventricular noncompaction is a rare type of cardiomyopathy, the genetics of which are poorly understood to date. Lamin A/C gene mutations have been associated with dilated cardiomyopathy and diseases of the conduction system, but rarely in left ventricular noncompaction cardiomyopathy. This report describes the cases of 4 family members with a lamin A/C gene mutation, 3 of whom had phenotypic expression of left ventricular noncompaction.
Left ventricular noncompaction (LVNC) is a distinct cardiomyopathy characterized by prominent trabeculations of the left ventricular (LV) myocardium. Patients with LVNC can develop progressive cardiac dysfunction that results in heart failure and increased risk of death. A variety of genes, primarily those encoding cardiac sarcomeric and cytoskeletal proteins, have been identified as causes of LVNC. At least one report identifies mutations in the gene lamin A/C (also known as LMNA), which encodes an inner nuclear membrane protein. Lamin A/C gene mutations have been associated with dilated cardiomyopathies, with and without conductionsystem disease.
We present a case report involving a family, 4 members of which had a heterozygous LMNA gene mutation-3 of whom had a phenotypic expression of LVNC.
Case Report
A 7yearold boy presented with syncope that appeared to be of vasovagal origin. During his initial evaluation at another facility, an echocardiogram showed a dilated left ventricle. These findingsdilated cardiomyopathy and recurrent syncope-prompted an electrophysiologic (EP) study and diagnostic cardiac catheterization. The EP study revealed no arrhythmias, and endomyocardial biopsy results showed myocyte hypertrophy without inflammation. Additional evaluation included the implantation of a loop recorder, which again did not identify any arrhythmias. The patient continued to have dilated cardiomyopathy with recurrent syncope and was eventually referred to us for further evaluation. During the initial visit for a second opinion, an echocardiogram showed LVNC with normal LV size, thickness, and function; the patient's LV enddiastolic dimension at that time was 4.67 cm (Z score, 1.57), his LV diastolic wall thickness was 0.7 cm (Z score, −0.50), his LV diastolic septal thickness was 0.8 cm (Z score, 0.19), and his shortening fraction was 41%.
Serial evaluations continued to reveal LVNC, with otherwise normal LV dimensions and function. Upon consultation, our cardiovascular genetics staff recommended genetic testing. A blood sample was sent to GeneDx (Gaithersburg, Md), where a panel of 27 genes known to cause dilated cardiomyopathy and LVNC was analyzed. This testing showed that the patient was heterozygous for a LMNA gene mutation: an amino acid substitution of arginine for cysteine (R644C) (Fig. 1) . No other abnormality was identified.
Fig. 1
The DNA sequence analysis of genomic DNA in the patient's proband reveals a CT transition in the LMNA gene at cDNA position c.1930 (arrow), which resulted in amino acid substitution of arginine for cysteine (R644C).
We next identified atrisk family members by using cascade genetic screening and yearly followup clinical evaluations. Cascade genetic testing in firstdegree relatives ( Fig. 2 ) revealed that the patient's brother was genotype positive and had LVNC with normal LV size and function on echocardiography (  Fig. 3) , his sister was genotype positive and had no abnormalities on echocardiography (Fig. 4) , his father was genotype positive and had LVNC with normal LV size and function on cardiac magnetic resonance (CMR), and his mother was genotype negative and had no abnormalities on echocardiography. Established diagnostic criteria were used for the evaluation of all family members, to determine whether LVNC was present.
Fig. 2
The patient's (P) pedigree and age of family members at most recent followup. Go to:
Go to:
has been restricted from athletics or other activities, and none has had any clinical problems or symptoms, disease progression, or evidence of dysrhythmias during the 4 years of monitoring.
Discussion
Left ventricular noncompaction is a distinct cardiomyopathy with established, albeit imperfect, diagnostic criteria. When LVNC is not associated with congenital heart disease, it can be subdivided into dilated, hypertrophic, mixed (dilated/hypertrophic), restrictive, and isolated (normal LV dimension and function). Recent studies have stratified patients in accordance with their increased risk of death.
Patients with LVNC are reportedly at risk of sudden death if they also have one of the following: LV dysfunction, LV dilation (LV enddiastolic dimension, >2 Zscores), LV hypertrophy, or arrhythmias. Reports of genetic mutations in LVNC remain uncommon, and only one previous case report to our knowledge has shown a LMNA gene mutation in a patient with LVNC.
The causal role (for LVNC) of the R644C mutation in the LMNA gene described in our family members is uncertain. It is possible that an unidentified gene not tested for in this family caused, or at least contributed to, the disease state; however, our findings link a gene known to cause abnormalities in the myocardium-dilated cardiomyopathy and conductionsystem abnormalities-to a family multiple members of which display clear phenotypic expression of LVNC. Although the population frequency of the R644C LMNA gene mutation has not been fully characterized, it appears to be exceedingly low. Muntoni and colleagues found no R644C mutations in 250 healthy control subjects drawn from the general population. The exact mechanism by which LMNA defects cause LVNC is difficult to know and was in any event beyond the scope of our foregoing case study. However, as HermidaPrieto and colleagues concluded, LMNA is very possibly causal in the setting of LVNC, and our report adds anecdotal evidence in support of that position. Certainly future studies aimed at characterizing the myocardium at a microscopic and molecular level will be helped by the growing evidence.
We should note that one family member from our series had the LMNA gene mutation and no identifiable cardiac abnormalities on testing, or by history and examination. This can be explained by a few hypotheses. First, the penetrance of this mutation is not 100%, and is actually very low, according to previous reports.
Therefore, although the girl in the family carries the heterozygous gene mutation, she has no phenotypic expression. Second, phenotypic expression can be quite variable, even among family members with the same mutation. Therefore, she might manifest a phenotypic disease different from that of other family members. We do not think that she will develop LVNC de novo, but she is at risk of dilated cardiomyopathy or cardiac conduction system disease-just with no phenotypic expression to date. For this reason, we have opted to continue monitoring her by means of periodic testing in our clinic.
As with all cardiomyopathies, identifying gene mutations can be important in further characterizing at risk family members and in providing insight into disease pathogenesis and future therapies. In this study, we identified atrisk family members by using cascade genetic screening and yearly followup clinical evaluations, with the goal of preventing the highrisk outcomes that can affect patients with LVNC. Ongoing evaluation of patients with LVNC and associated LMNA gene mutations will be important in the understanding of the risk profile for this unique cardiomyopathy.
Conclusion
Although LMNA gene mutations have been associated with dilated cardiomyopathies and conduction system disease, they have rarely been reported in the presence of LVNC. Ongoing investigation of the frequency of LMNA mutations in LVNC is important, for it might further expand our knowledge of the disease process and aid us in identifying atrisk firstdegree relatives of LVNC patients. 
